rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2003-1354rsp-1218Research ArticleСтатьиArticlesАтерогенный эффект сыворотки крови больных системной красной волчанкойAtherogenic effect of systemic lupus erythematosus pts blood serumАлекбероваЗемфира СадуллаевнаAlekberovaZ S-GerasimovaE VGerasimovaE V-SobeninI ASobeninI A-200315062003413№3 (2003)2123Copyright © Алекберова З.С., Gerasimova E.V., Sobenin I.A., 20032003Алекберова З.С., Gerasimova E.V., Sobenin I.A.Alekberova Z.S., Gerasimova E.V., Sobenin I.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/1218

Цель. Оценить связь атерогенности сыворотки крови больных СКВ с активностью заболевания и приемом глюкокортикоидов (ГК). Материал и методы. В исследование включены 40 молодых женщин с СКВ: 20 больных, не получающие Г'К, - 1-ая группа и 20 больных, длительно леченных малыми дозами ГК (< 15 мг/сут). - 2-ая группа. Группы различались по длительности и активности СКВ (2,6±1,8 и 16,2±1,9 лет; 17,5±4,8 и 5,7±3,8 баллов по SLEDA1 соответственно). Контрольная группа состояла из 20 здоровых женщин. Атерогенность сыворотки определяли в культуре перитонеальных макрофагов мышей линии BALB/c по накоплению внутриклеточного холестерина (ХС), индуцированному сывороткой крови больных. Результаты. 90% сывороток больных и лишь 15% сывороток здоровых лиц обладали атерогенны- ми свойствами, то есть вызывали в среднем 2-кратное накопление ХС в культивируемых клетках. Частота выявления атерогенных свойств сыворотки у больных, длительно страдающих СКВ, была несколько выше. Атерогенность сыворотки крови была выше в 1-ой группе, чем во 2-ой (221±13% и 185±11%, р=0,044). Атерогенность коррелировала с индексом активности SLEDAI ( г=0,82, р=0,04). Ассоциации с показателями липидного спектра крови (общий ХС, триглицериды, ХС липопротеидов низкой плотности (ЛНП) и ХС липопротеидов высокой плотности (ЛВП)) получено не было. • Заключение. Имеется прямая зависимость атерогенности сыворотки от активности заболевания, что указывает на роль иммунологических нарушений в атерогенезе у больных СКВ

Objective. To study relation of SLE pts blood serum atherogenicity to disease activity and corticosteroids (CS) administration. Methods. 40 young women with SLE were included. 20 of them did not received CS (group 1) and 20 were treated with small doses of CS (<15 mg/day) for a long time (group 2). Duration of the disease was longer in group 2 and SLEDAI indexes were higher in group 1. Control group consisted of 20 healthy women. Serum atherogenicity was examined in BALB/c mice peritoneal macrophages culture by accumulation of intracellular cholesterol (CH) induced by pts blood serum. Results. Most of pts blood serum (90%) and only 15% control blood serum possessed atherogenic potential causing 2-fold rise of intracellular cholesterol level. Frequency of serum atherogenic activity in pts having SLE for a long time was higher. Serum atherogenic activity in group 1 was higher than in group 2 (221±13% and 185±11 % respectively, p=0,044). Atherogenicity correlated with SLEDAI index (r=0,82, p=0,04). No correlation was found between atherogenicity and lipid fractions. Conclusion. Serum atherogenecity is directly dependent on disease activity what shows the significance of immunological changes in atherogenesis in SLE pts

системная красная волчанкаатерогенностьатеросклерозsystemic lupus erythematosusatherogenecityatherosclerosisReferences<div><p>Маянский Ф.Н. Конденцнонирование нейтрофила. Успехи соврем, биолог., 1990, Т.104, вып. I, 90-105.</p><p>Тертов В.В. Множественно-модифицированные липо- протеиды низкой плотности, циркулирующие в крови человека. Ангиолог. сос.хирург., 1999, 5, 218-240.</p><p>Alarcon-Scgovia D. Pathogenesis of systemic lupus erythematosus: possible participation of antiphospholipid antibodies. lsr.J. Med. Sci., 1989, 25. 669-672.</p><p>Bennet R.M., Gabor G.T., Merritt M.J. DNA binding to human leukocytes: evidence for a receptor mediated association, internalization and degradation of DNA. J. Clin. Invest., 1985, 76, 2182-2188.</p><p>Frank M.M., Hamburger M.I., Lawley T.J.et al. Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N. Engl J Med., 1976, 300, 518-521.</p><p>Goldstein J.L., Ho G.K., Basu S.K., Brown M.S. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Nat. Acad. Sci USA, 1979, 78, 333-337.</p><p>Kabakov A.E., Tertov V.V., Saenko V.A. The atherogenic effect of lupus sera: systemic lupus erythematosus-derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta. Clin. Immunol. Immunopathol., 1992, 62,3, 214-220.</p><p>Kabakov A.E., Saenko V.A., Poverenny A.M. LDL-medi- ated interacthion of DNA and DNA-anti-DNA immune complexes with cell surface. Clin. Exp. Immunol., 1991, 83, 357-363.</p><p>Kiener P., Rankin B. Davis P. et al. Immune complexes of LDL induce atherogenic responses in human monocytic cells. Arterioscler. Thromb. Vase. Biol., 1995, 15, 990-999.</p><p>Klimov A.N., Denisenko A.D., Vinogradov A.G. et al. Accumulation of cholesteryl esters in macrophages incubated with human lipoprotein-antibody autoimmune complex. Atherosclerosis, 1988. 74. 41-46.</p><p>Koffler D. Immunopathogenesis of systemic lupus erythematosus. Ann. Rev. Med., 1974, 25, 149-154.</p><p>Kostner G.M., Zechner R., Bihar-Varga M„ Gruber E. The interaction of human plasma LDL with glycosamino- glvcans: influence of the chemical composition. Lipids, 1985, 20, 24-29.</p><p>Lake R.A., Morgan A., Henderson B. et al. A key role for fibronectin in the sequential binding of native dsDNA and monoclonal anti-DNA antibodies to components of the extracellular matrix: its possible significance in glomerulonephritis. Immunology, 1985, 54, 389-395.</p><p>Lopes-Virella M.F., Virella G. Atherosclerosis and autoimmunity. Clin. Immunol. Immunopathol., 1994, 73, 2, 155167.</p><p>Parthasarathy S., Printz D., Boyd D. et al. Macrophage oxidation of low density lipoprotein generates a modified form recognized bY the scavenger receptor. Atherosclerosis, 1986, 6. 505-510.'</p><p>Ross R. Atherosclerosis - an inflammatory disease. New Engl. J. Med., 1999, 340, 115-126.</p><p>Schwartz C.J., Valente A.J., Spragut E.A. et al.: Monocyte-macrophage participation in atherogenesis: Inflammatory components of pathogenesis. Semin. Thromb. Hemost., 1986, 12,79-86.</p><p>Smeenk R., Lelij G., Aarden L. Avidity of antibodies to dsDNA: comparison 1FT on Crithidia luciliae. Farr assay and PEG assay. J. Immunol., 1982 b, 128, 73-81.</p><p>Tan E.N., Cohen A.S., Fries J.F. et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthr. Rheum., 1982, 25, 1271.</p><p>Tertov V.V., Orekhov A.N., Nikitina N.A. et al. Peritoneal macrophages: a model for detecting atherogenic potential in patients’ blood serum. Ann. Med., 1989, 21 (6), 455-459.</p><p>Tertov V.V., Orekhov A.N., Ryong L.N., Smirnov V.N. Intracellular cholesterol accumulation is accompanied by enhanced proliferative activity of human aortic intimal cell. Tissue Cell, 1988, 20. 849-851.</p></div><br /><div><p>Маянский Ф.Н. Конденцнонирование нейтрофила. Успехи соврем, биолог., 1990, Т.104, вып. I, 90-105.</p><p>Тертов В.В. Множественно-модифицированные липо- протеиды низкой плотности, циркулирующие в крови человека. Ангиолог. сос.хирург., 1999, 5, 218-240.</p><p>Alarcon-Scgovia D. Pathogenesis of systemic lupus erythematosus: possible participation of antiphospholipid antibodies. lsr.J. Med. Sci., 1989, 25. 669-672.</p><p>Bennet R.M., Gabor G.T., Merritt M.J. DNA binding to human leukocytes: evidence for a receptor mediated association, internalization and degradation of DNA. J. Clin. Invest., 1985, 76, 2182-2188.</p><p>Frank M.M., Hamburger M.I., Lawley T.J.et al. Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N. Engl J Med., 1976, 300, 518-521.</p><p>Goldstein J.L., Ho G.K., Basu S.K., Brown M.S. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Nat. Acad. Sci USA, 1979, 78, 333-337.</p><p>Kabakov A.E., Tertov V.V., Saenko V.A. The atherogenic effect of lupus sera: systemic lupus erythematosus-derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta. Clin. Immunol. Immunopathol., 1992, 62,3, 214-220.</p><p>Kabakov A.E., Saenko V.A., Poverenny A.M. LDL-medi- ated interacthion of DNA and DNA-anti-DNA immune complexes with cell surface. Clin. Exp. Immunol., 1991, 83, 357-363.</p><p>Kiener P., Rankin B. Davis P. et al. Immune complexes of LDL induce atherogenic responses in human monocytic cells. Arterioscler. Thromb. Vase. Biol., 1995, 15, 990-999.</p><p>Klimov A.N., Denisenko A.D., Vinogradov A.G. et al. Accumulation of cholesteryl esters in macrophages incubated with human lipoprotein-antibody autoimmune complex. Atherosclerosis, 1988. 74. 41-46.</p><p>Koffler D. Immunopathogenesis of systemic lupus erythematosus. Ann. Rev. Med., 1974, 25, 149-154.</p><p>Kostner G.M., Zechner R., Bihar-Varga M„ Gruber E. The interaction of human plasma LDL with glycosamino- glvcans: influence of the chemical composition. Lipids, 1985, 20, 24-29.</p><p>Lake R.A., Morgan A., Henderson B. et al. A key role for fibronectin in the sequential binding of native dsDNA and monoclonal anti-DNA antibodies to components of the extracellular matrix: its possible significance in glomerulonephritis. Immunology, 1985, 54, 389-395.</p><p>Lopes-Virella M.F., Virella G. Atherosclerosis and autoimmunity. Clin. Immunol. Immunopathol., 1994, 73, 2, 155167.</p><p>Parthasarathy S., Printz D., Boyd D. et al. Macrophage oxidation of low density lipoprotein generates a modified form recognized bY the scavenger receptor. Atherosclerosis, 1986, 6. 505-510.'</p><p>Ross R. Atherosclerosis - an inflammatory disease. New Engl. J. Med., 1999, 340, 115-126.</p><p>Schwartz C.J., Valente A.J., Spragut E.A. et al.: Monocyte-macrophage participation in atherogenesis: Inflammatory components of pathogenesis. Semin. Thromb. Hemost., 1986, 12,79-86.</p><p>Smeenk R., Lelij G., Aarden L. Avidity of antibodies to dsDNA: comparison 1FT on Crithidia luciliae. Farr assay and PEG assay. J. Immunol., 1982 b, 128, 73-81.</p><p>Tan E.N., Cohen A.S., Fries J.F. et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthr. Rheum., 1982, 25, 1271.</p><p>Tertov V.V., Orekhov A.N., Nikitina N.A. et al. Peritoneal macrophages: a model for detecting atherogenic potential in patients’ blood serum. Ann. Med., 1989, 21 (6), 455-459.</p><p>Tertov V.V., Orekhov A.N., Ryong L.N., Smirnov V.N. Intracellular cholesterol accumulation is accompanied by enhanced proliferative activity of human aortic intimal cell. Tissue Cell, 1988, 20. 849-851.</p></div><br />

The authors declare that there are no conflicts of interest present.